202 related articles for article (PubMed ID: 37017995)
1. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
[TBL] [Abstract][Full Text] [Related]
2. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
3. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
Gan M; Zhang C; Qiu L; Wang Y; Bao H; Yu R; Liu R; Wu X; Shao Y; Hou P; Fei Z
Cancer Med; 2022 Nov; 11(21):4070-4078. PubMed ID: 35586877
[TBL] [Abstract][Full Text] [Related]
4. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.
Zhu G; Benayed R; Ho C; Mullaney K; Sukhadia P; Rios K; Berry R; Rubin BP; Nafa K; Wang L; Klimstra DS; Ladanyi M; Hameed MR
Mod Pathol; 2019 May; 32(5):609-620. PubMed ID: 30459475
[TBL] [Abstract][Full Text] [Related]
6. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma.
Planas-Paz L; Pliego-Mendieta A; Hagedorn C; Aguilera-Garcia D; Haberecker M; Arnold F; Herzog M; Bankel L; Guggenberger R; Steiner S; Chen Y; Kahraman A; Zoche M; Rubin MA; Moch H; Britschgi C; Pauli C
EMBO Mol Med; 2023 Apr; 15(4):e16863. PubMed ID: 36779660
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY; Seligson ND; Hays JL; Miles WO; Chen JL
JCO Precis Oncol; 2022 Feb; 6():e2100211. PubMed ID: 35108033
[TBL] [Abstract][Full Text] [Related]
8. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
10. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.
Li X; Seebacher NA; Hornicek FJ; Xiao T; Duan Z
Cancer Lett; 2018 Dec; 439():66-77. PubMed ID: 30223067
[TBL] [Abstract][Full Text] [Related]
11. The Landscape of Immunotherapy for Retroperitoneal Sarcoma.
Gingrich AA; Nassif EF; Roland CL; Keung EZ
Curr Oncol; 2023 Feb; 30(2):2144-2158. PubMed ID: 36826126
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.
Panagi M; Pilavaki P; Constantinidou A; Stylianopoulos T
Theranostics; 2022; 12(14):6106-6129. PubMed ID: 36168619
[TBL] [Abstract][Full Text] [Related]
13. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
14. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
16. [Systemic therapy of sarcomas : New biomarkers and therapeutic strategies].
Bauer S; Dirksen U; Schildhaus HU
Pathologe; 2019 Jul; 40(4):436-442. PubMed ID: 31243550
[TBL] [Abstract][Full Text] [Related]
17. EWSR1-NFATC2 Translocation-associated Sarcoma Clinicopathologic Findings in a Rare Aggressive Primary Bone or Soft Tissue Tumor.
Wang GY; Thomas DG; Davis JL; Ng T; Patel RM; Harms PW; Betz BL; Schuetze SM; McHugh JB; Horvai AE; Cho SJ; Lucas DR
Am J Surg Pathol; 2019 Aug; 43(8):1112-1122. PubMed ID: 30994538
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
19. Small Round Blue Cell Sarcoma Other Than Ewing Sarcoma: What Should an Oncologist Know?
Davis JL; Rudzinski ER
Curr Treat Options Oncol; 2020 Sep; 21(11):90. PubMed ID: 32875423
[TBL] [Abstract][Full Text] [Related]
20. Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.
Brahmi M; Gaspar N; Gantzer J; Toulmonde M; Boudou-Rouquette P; Bompas E; Firmin N; Valentin T; Cancel M; Duffaud F; Bertucci F; Perrin C; Dufresne A; Marec-Bérard P; Jean-Denis M; Ray-Coquard I; Le Loarer F; Pierron G; Tirode F; Blay JY; Watson S
Cancer Med; 2023 Apr; 12(7):7801-7807. PubMed ID: 36537582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
